Keeley Teton Advisors LLC Sells 2,163 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Keeley Teton Advisors LLC lowered its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 13.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 13,637 shares of the specialty pharmaceutical company’s stock after selling 2,163 shares during the quarter. Keeley Teton Advisors LLC’s holdings in Supernus Pharmaceuticals were worth $493,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in SUPN. Vanguard Group Inc. lifted its stake in Supernus Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock worth $222,411,000 after acquiring an additional 22,852 shares during the period. Geode Capital Management LLC raised its holdings in Supernus Pharmaceuticals by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company’s stock worth $54,633,000 after purchasing an additional 28,517 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Supernus Pharmaceuticals by 9.2% in the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock worth $41,248,000 after purchasing an additional 95,777 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock valued at $27,242,000 after purchasing an additional 40,968 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Supernus Pharmaceuticals by 4.5% during the fourth quarter. Invesco Ltd. now owns 508,069 shares of the specialty pharmaceutical company’s stock valued at $18,372,000 after buying an additional 22,027 shares during the period.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $30.71 on Thursday. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of 28.70 and a beta of 0.90. The firm has a 50 day moving average price of $33.06 and a 200-day moving average price of $35.02. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. This represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have weighed in on the company. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Cantor Fitzgerald restated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.